Lamivudine/Zidovudine Viatris (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside analogues that, after intracellular phosphorylation, mimic natural nucleosides. When incorporated into viral DNA by HIV reverse transcriptase, they cause premature chain termination, blocking viral replication and reducing the amount of virus in the bloodstream.

The specific dose and dosing schedule are determined by the treating physician based on the patient’s clinical condition, weight, renal function, and other medications. Healthcare providers follow established guidelines and adjust the regimen as needed for optimal viral suppression.

Safety in pregnancy and lactation must be evaluated by a qualified clinician. The drug may be used when the benefits to the mother outweigh potential risks to the fetus, and breastfeeding decisions should consider the infant’s exposure through milk and the mother’s health status.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/Zidovudine is a fixed‑dose NRTI combination offering convenience compared with separate tablets. Compared with newer agents such as tenofovir/emtricitabine, it may have a different safety profile, including a higher risk of anemia and neutropenia, but remains an effective component of many established regimens.

The product should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister or container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lamivudine/Zidovudine is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication is part of a broader antiretroviral regimen and should be taken consistently at the same times each day to maintain therapeutic levels.

Serious adverse events include severe anemia, neutropenia, lactic acidosis, hepatomegaly with steatosis, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for hematologic and hepatic abnormalities, and any signs of severe toxicity require immediate medical attention.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any component of the formulation should avoid the drug. Caution is also advised for patients with pre‑existing severe anemia, bone‑marrow suppression, or significant liver disease, and use should be guided by a healthcare professional.